LUNG: Common and Uncommon Emerging Indications for Thoracic Cancers

Speaker(s)

• 

  Joe Chang, MD

  Professor
  MD Anderson Cancer Center Houston

  Disclosure(s): BMS: Grant/Research Support (Ongoing); IBA: Consultant/Advisory Board (Ongoing); Regeneron: Consultant/Advisory Board (Ongoing)

  PDF Slides
• 

  Andreas Rimner, MD (he/him/his)

  Vice Chair
  Department of Radiation Oncology, University of Freiburg
  Loerrach, Baden-Wurttemberg, Germany

  Disclosure(s): AstraZeneca: Consultant/Advisory Board (Terminated, January 19, 2024), Grant/Research Support (Terminated, January 19, 2024), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated, January 19, 2024); Boehringer Ingelheim: Grant/Research Support (Terminated, January 19, 2024), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated, January 19, 2024); Merck: Consultant/Advisory Board (Terminated, January 19, 2024), Grant/Research Support (Terminated, January 19, 2024), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated, January 19, 2024)

  PDF Slides

Presentations:

• 8:30 AM – 9:30 AM ET

  Managing Challenging Early Stage NSCLC Cases and Exploring the Combination of Stereotactic Ablative Radiotherapy and Immunotherapy
  

  Speaker: Joe Chang, MD – MD Anderson Cancer Center Houston
• 8:30 AM – 9:30 AM ET

  Demystifying Uncommon Thoracic Malignancies: Optimizing Management for Thymic Tumors and Pleural Mesothelioma
  

  Speaker: Andreas Rimner, MD (he/him/his) – Department of Radiation Oncology, University of Freiburg